Uncategorized

Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease

by Business Wire • 2019/12/03 • 0 Comments

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, announced today positive top-line results from Part 1 of the adaptive Phase 3 RENEW Trial of topical ocular reproxalap in patients with dry eye disease. “To our knowledge, reproxalap is the first topical dry eye disease drug to demonstrate statistically s

Full Story →

← Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in Europe

Study Shows Superior Success Rate for ExTra ELT Compared With Trabectome in Patients With Glaucoma Plus Cataract Surgery →

Post navigation